The REGENOSIS GERO-SCIENCE FUND (“Regenosis” or the “Fund”) offers investors an opportunity to participate in the fast-evolving geroscience biomedical sector through its investments in businesses focused on human longevity, lifespan and healthspan extension.
The Fund expects this sector to be a multi-trillion dollar opportunity by 2050 given the ageing global population and increasing health consciousness.
Regenosis is an open-ended fund that aims to deliver stable long term capital appreciation by investing in public and private healthcare assets, biomedical intellectual property, and businesses each with assessed probable successful medical technology over a three-to-five-year horizon.
The Fund is registered in the Cayman Islands as a segregated portfolio of Edge Capital Fund SPC, with SGX listed TalkMed Group Limited and Singapore’s pioneering cord blood bank StemCord Pte Ltd as anchor investors and is advised by a panel of international key opinion leaders in geroscience and senior specialist doctors from Singapore.
Prof Brian Kennedy
Distinguished Professor, Department of Biochemistry and Physiology, Yong Loo Lin School of Medicine, National University of Singapore
Prof. Matt Kaeberlein
Professor, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA
Prof. Zeng Xianmin
Visiting Professor, Centre for Healthy Ageing / Physiology, National University of Singapore
Dr. Ang Peng Tiam
Senior Consultant, Medical Oncologist, Parkway Cancer Centre, CEO TalkMed Group
Dr. Teo Cheng Peng
Senior Consultant, Haematologist, Parkway Cancer Centre
Dr Khoo Kei Siong
Senior Consultant, Medical Oncologist, Parkway Cancer Centre
Dr. Leong See Odd
Senior Consultant, Nephrologist, Gleneagles Hospital,